SCHEMBL23213643

SCHEMBL23213643

Cc1c(Cl)cc(OC(N)=O)cc1CN1CCN(C)CC1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.42
KDM4E B2RXH2 6/20 0.42
SOS1 Q07889 1/20 0.41
POLB P06746 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
ADORA1 P30542 1/20 0.40
GAA P10253 4/20 0.39
GLA P06280 3/20 0.39
HPGD P15428 3/20 0.39
HIF1A Q16665 3/20 0.39
MAPT P10636 1/20 0.39
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
ABL1 P00519 2/20 0.38
CHKA P35790 1/20 0.38
METAP2 P50579 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ERAP1 Q9NZ08 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29177281 0.86 HCRTR1 (0.43) ALDH1A1KDM4EPOLBTDP1GAA
SCHEMBL29175923 0.84 ALDH1A1 (0.53) ALDH1A1KDM4ESOS1POLBTDP1
SCHEMBL23212903 0.82 PARP1 (0.43) ALDH1A1KDM4EPOLBTDP1LMNA
SCHEMBL29177236 0.78 KMT2A (0.39) ALDH1A1KDM4EGAAGLAHPGD
SCHEMBL23213589 0.76 LMNA (0.50) ALDH1A1KDM4EPOLBTDP1ADORA1
SCHEMBL29716296 0.76 LMNA (0.50) ALDH1A1KDM4EPOLBTDP1ADORA1
SCHEMBL27290060 0.75 ALDH1A1 (0.50) ALDH1A1KDM4EPOLBTDP1GAA
SCHEMBL23213588 0.74 ABL1 (0.49) ALDH1A1KDM4EPOLBTDP1ADORA1
SCHEMBL23213515 0.74 CHRNA3 (0.38)
SCHEMBL23213534 0.73 PDE10A (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS MONTE ROSA THERAPEUTICS AG (CH) 2024-07-04 US disclosed
EP-4313047-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS Monte Rosa Therapeutics, Inc. (US) 2024-02-07 EP disclosed
WO-2021069705-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS (CH) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS UPF1, NSUN2, RTF2 ALDH1A1 4150/4885KDM4E 3979/4885SOS1 1636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.